Alkermes PLC ALKS
News
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024
Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
Alkermes plc Reports Second Quarter 2024 Financial Results
Alkermes to Report Second Quarter Financial Results on July 24, 2024